7. STOCKHOLDERS' EQUITY (Details 2) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total stock-based compensation expense	$ 676,548	$ 637,263
Research and development
Total stock-based compensation expense	93,574	86,523
Plasma centers
Total stock-based compensation expense	7,244	11,540
Selling, general and administrative
Total stock-based compensation expense	523,889	498,471
Cost of product revenue
Total stock-based compensation expense	$ 51,841	$ 40,729